Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
BioSpace12h
Regeneron Loses Appeal to Block Amgen’s Eylea Biosimilar
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Regeneron's Injunction on Eylea Biosimilar Holds Up on Appeal
The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...
Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices- Hagens Berman
At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...
Investing19d
Regeneron's SWOT analysis: biotech stock faces eylea challenges, pipeline promise
2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...
Endpoints News3d
Fed­er­al Cir­cuit rul­ing al­lows Am­gen's Eylea biosim­i­lar to stay on the mar­ket
The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...
Life Sciences IP Review11d
Regeneron edges closer to Eylea market exclusivity amid biosimilar threats
New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...
Nasdaq11d
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
Adjusted SG&A expenses increased 9% to $681 million due to higher commercialization-related expenses to support the launch of Eylea HD and higher headcount-related costs. Regeneron recorded ...
Investing19d
Regeneron’s SWOT analysis: biotech stock faces eylea challenges, pipeline promise
2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...